EC Number   |
Application  |
Reference |
|---|
   3.4.19.3 | analysis |
application to N-terminal pyroglutamyl unblocking prior to Edman sequential degradation in peptide and protein sequencing |
95300, 95303 |
| 3.4.19.3 | analysis |
pyroglutamyl aminopeptidase is an auxiliary enzyme in a spectrometric assay for glutaminyl cyclase activity. It is a fast, continuous, and reliable determination of glutaminyl cyclase activity, even in the presence of ammonium ions, during the course of protein purification and enzymatic analysis |
649314 |
| 3.4.19.3 | analysis |
the enzyme may be a useful single-test adjunct for distinguishing Staphylococcus aureus from Staphylococcus delphini and other members of the Staphylococcus intermedius group |
-, 754260 |
| 3.4.19.3 | medicine |
analysis of enzymic activity in serum of controls and patients diagnosed with pancreatitis, hepatitis, and liver cirrhosis. Pyroglutamyl-aminopeptidase activity decreases selectively in liver cirrhosis compared with all the rest of groups |
731717 |
| 3.4.19.3 | medicine |
diabetes mellitus affects the levels of hippocampal and hypothalamic PAP-I activities, which may change the metabolic control of its susceptible physiological peptide substrates in the brain |
682252 |
| 3.4.19.3 | medicine |
examination of Peptoclostridium difficile isolates from children with hematological malignancies, diarrhoea and from healthy neonates. All strains from children with hematological malignancies react with the substrate for L-pyrrolidone arylamidase |
727346 |
| 3.4.19.3 | medicine |
healthy post-menopausal women show higher values of pyroglutamyl-peptidase I activity than pre-menopausal women. No differences are found in serum pyroglutamyl-peptidase activity between pre- and post-menopausal women with breast cancer. Only post-menopausal women with breast cancer show lower values of pyroglutamyl-peptidase activity than control women |
731568 |
| 3.4.19.3 | medicine |
overexpression of active PPI in Leishmania major impairs differentiation from the procyclic promastigote to the infective metacyclic promastigote. PPI does not protect against the natural antimicrobial peptide gomesin |
681817 |
| 3.4.19.3 | medicine |
profiles of macrophage and renal PAP activities may be considered into the elaboration of new potential strategies for preventing nephrotoxicity during cyclosporin treatment |
680172 |
| 3.4.19.3 | medicine |
the natural oligosaccharide gum from Hakea gibbosa is an effective non-competitive inhibitor. The natural gum may be a promising additive not only for its sustained-release and mucoadhesive properties, but also for its ability to slow the enzymatic degradation of therapeutic polypeptides incorporated in dosage forms |
651549 |
